For: | Raghow R. Statins redux: A re-assessment of how statins lower plasma cholesterol. World J Diabetes 2017; 8(6): 230-234 [PMID: 28694924 DOI: 10.4239/wjd.v8.i6.230] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v8/i6/230.htm |
Number | Citing Articles |
1 |
Khaled Maged, Magda M. El-Henawee, Soad S. Abd El-Hay. Development and validation of an eco-friendly HPLC–UV method for determination of atorvastatin and vitamin D3 in pure form and pharmaceutical formulation. BMC Chemistry 2023; 17(1) doi: 10.1186/s13065-023-00975-6
|
2 |
Romeo-Gabriel Mihăilă. Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review. Current Cardiology Reviews 2020; 16(1): 36 doi: 10.2174/1573403X15666190522100041
|
3 |
Ye Seul Yang, Seo Young Lee, Jung-Sun Kim, Kyung Mook Choi, Kang Wook Lee, Sang-Chol Lee, Jung Rae Cho, Seung-Jin Oh, Ji-Hyun Kim, Sung Hee Choi. Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. Endocrinology and Metabolism 2020; 35(2): 367 doi: 10.3803/EnM.2020.35.2.367
|
4 |
Hesham Salah El Din Taha, Hala Mahfouz Badran, Hossam Kandil, Nabil Farag, Abbas Oraby, Magdy El Sharkawy, Khaled Shokry, Fouad Fawzy, Hossam Mahrous, Juliette Bahgat, Mina Samy, Mirna Mamdouh Shaker. Egyptian practical guidance in lipid management 2020. The Egyptian Heart Journal 2021; 73(1) doi: 10.1186/s43044-021-00140-1
|
5 |
Arrigo F.G. Cicero, Matteo Landolfo, Fulvio Ventura, Claudio Borghi. Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opinion on Pharmacotherapy 2019; 20(10): 1277 doi: 10.1080/14656566.2019.1604687
|
6 |
Hitomi ODA, Aiko HAGA, Kaoru KOYAMA, Kureha GOKITA, Ran AKIYAMA, Takumi KOMIYA, Shinogu HASEGAWA, Toshinori SAKO, Akihiro MORI. Treatment of Ezetimibe lowers total and low-density lipoprotein cholesterol in hypercholesterolemic dogs with hyperadorenocorticism. Journal of Veterinary Medical Science 2024; 86(4): 363 doi: 10.1292/jvms.23-0461
|
7 |
Dragan B. Djordjevic, Aleksandar D. Dordevic, Dragan B. Lovic. Dyslipidemia: Contemporary Therapy Options in Terms of Worldwide Guidelines. Current Pharmacology Reports 2019; 5(2): 87 doi: 10.1007/s40495-019-00173-w
|
8 |
Lijun Wang, Weiwei Zhou, Manyun Guo, Yiming Hua, Baihua Zhou, Xinyin Li, Xinxin Zhang, Jiakun Dong, Xiumei Yang, Yang Wang, Yue Wu, Jianqing She, Jianjun Mu. The gut microbiota is associated with clinical response to statin treatment in patients with coronary artery disease. Atherosclerosis 2021; 325: 16 doi: 10.1016/j.atherosclerosis.2021.03.007
|
9 |
Rajiv Gupta, Shivani Sharma, Rajdeep Kaur, Kumud Upadhyaya. An overview of pleiotropic effect of statins in cardiovascular disease. Pharmacy & Pharmacology International Journal 2018; 6(6) doi: 10.15406/ppij.2018.06.00214
|
10 |
Musawenkosi Ndlovu, June C. Serem, Megan J. Bester, Zeno Apostolides, Andrew R. Opoku, Rebamang A. Mosa, Akihiro Inazu. Two Triterpenoids, ARM‐2 and RA‐5, From Protorhus longifolia Exhibit the Potential to Modulate Lipolysis and Lipogenesis in Cultured 3T3‐L1 Adipocytes. Journal of Lipids 2024; 2024(1) doi: 10.1155/2024/3972941
|
11 |
Donatella Zodda, Rosario Giammona, Silvia Schifilliti. Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy 2018; 6(1): 10 doi: 10.3390/pharmacy6010010
|
12 |
Musawenkosi Ndlovu, June C. Serem, Mamoalosi A. Selepe, Andrew R. Opoku, Megan J. Bester, Zeno Apostolides, Rebamang A. Mosa. Triterpenoids from Protorhus longifolia Exhibit Hypocholesterolemic Potential via Regulation of Cholesterol Biosynthesis and Stimulation of Low-Density Lipoprotein Uptake in HepG2 Cells. ACS Omega 2023; 8(34): 30906 doi: 10.1021/acsomega.3c01995
|
13 |
Leo Tsui, Peiying Ye, Shiling Xu, Yuan Lin, Bin Chen, Sy-Ping Chen, Ruoh-Yi Cheng. Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis. European Journal of Hospital Pharmacy 2023; 30(e1): e82 doi: 10.1136/ejhpharm-2022-003333
|